Chang Jang-Yang, Lin Chyun-Feng, Pan Wen-Yu, Bacherikov Valeriy, Chou Ting-Chao, Chen Ching-Huang, Dong Huajin, Cheng Shu-Yun, Tasi Tsong-Jen, Lin Yi-Wen, Chen Kuo-Tung, Chen Li-Tzong, Su Tsann-Long
Division of Cancer Research, National Health Research Institutes, Taipei, Taiwan.
Bioorg Med Chem. 2003 Nov 17;11(23):4959-69. doi: 10.1016/j.bmc.2003.09.001.
A series of new analogues of 3-(9-acridinylamino)-5-hydroxymethylaniline (AHMA, 1) and AHMA-ethylcarbamate (2) were synthesized by introducing an O-alkylcarboxylic acid esters to the CH(2)OH function, displacing the CH(2)OH function with a dimethylaminocarboxamido group or with a methyl function introduced at the meta-, para- or ortho-position to the NH(2) group to form 5-(9-acridinylamino)-m-toluidines (AMTs), 5-(9-acridinylamino)-p-toluidines (APTs) or 5-(9-acridinylamino)-o-toluidines (AOTs), respectively. The inhibitions of a variety of human tumor cell growth, interactions with DNA as well as inhibitory effect against topoisomerase II (Topo II) of these new agents were studied. Among AMT, APT and AOT derivatives with dimethylaminoethylcarboxamido and Me at C4 and C5 of acridine moiety (i.e., 21c, 23c and 26c) were more cytotoxic than AHMA (1) and AHMA-ethylcarbamate (2), depending upon the tumor cell line tested. Detailed structure-activity relationships of the new analogues were studied.
通过将O-烷基羧酸酯引入到CH(2)OH官能团、用二甲基氨基甲酰胺基取代CH(2)OH官能团或在NH(2)基团的间位、对位或邻位引入甲基官能团,分别合成了一系列3-(9-吖啶基氨基)-5-羟甲基苯胺(AHMA, 1)和AHMA-乙基氨基甲酸酯(2)的新类似物,以形成5-(9-吖啶基氨基)-间甲苯胺(AMTs)、5-(9-吖啶基氨基)-对甲苯胺(APTs)或5-(9-吖啶基氨基)-邻甲苯胺(AOTs)。研究了这些新试剂对多种人类肿瘤细胞生长的抑制作用、与DNA的相互作用以及对拓扑异构酶II(Topo II)的抑制作用。在吖啶部分的C4和C5位带有二甲基氨基乙基甲酰胺基和甲基的AMT、APT和AOT衍生物(即21c、23c和26c)比AHMA(1)和AHMA-乙基氨基甲酸酯(2)更具细胞毒性,这取决于所测试的肿瘤细胞系。研究了新类似物详细的构效关系。